Page tree

You are viewing an old version of this page. View the current version.

Compare with Current View Page History

« Previous Version 2 Next »


Date

20211207

Document Version

0.1

Release Status

PREPRODUCTION

  

© 2024 International Health Terminology Standards Development Organisation.  All rights reserved.  SNOMED CT® was originally created by the College of American Pathologists.

This document forms part of the SNOMED CT® Ireland Extension release distributed by International Health Terminology Standards Development Organisation, trading as SNOMED International, and is subject to the SNOMED CT® Affiliate License, details of which may be found at https://www.snomed.org/snomed-ct/get-snomed

No part of this document may be reproduced or transmitted in any form or by any means, or stored in any kind of retrieval system, except by an Affiliate of SNOMED International in accordance with the SNOMED CT® Affiliate License. Any modification of this document (including without limitation the removal or modification of this notice) is prohibited without the express written permission of SNOMED International.

Any copy of this document that is not obtained directly from SNOMED International [or a Member of SNOMED International] is not controlled by SNOMED International, and may have been modified and may be out of date. Any recipient of this document who has received it by other means is encouraged to obtain a copy directly from SNOMED International [or a Member of SNOMED International. Details of the Members of SNOMED International may be found at http://www.snomed.org/members/].







Page At A Glance

1 Introduction

SNOMED CT terminology provides a common language that enables a consistent way of indexing, storing, retrieving, and aggregating clinical data across specialties and sites of care.

The International Health Terminology Standards Development organisation (IHTSDO®), trading as SNOMED International, maintains the SNOMED CT technical design, the content architecture, the SNOMED CT content (includes the concepts table, the descriptions table, the relationships table, a history table, and ICD mappings), and related technical documentation.

The SNOMED CT Switzerland Extension - packages these components for release every December and July, to be used with the latest SNOMED CT International Edition release.

The same content can be viewed online using the SNOMED CT browser, and???????Switzerland's own???????? website


2 Background

This document provides a summarized description of the content changes included in the December 2021 Production release of the SNOMED Clinical Terms® Managed Service Switzerland Extension package.

It will also include technical notes detailing the known issues which have been identified (should any of these exist). These are content or technical issues where the root cause is understood, and the fix has been discussed and agreed, but has yet to be implemented.

This Switzerland Extension package is dependent upon, and should therefore be consumed in conjunction with, the SNOMED CT® July 2021 International Edition release.

2.1 Scope

This document is written for the purpose described above and is not intended to provide details of the technical specifications for SNOMED CT or encompass every change made during the release.


3 Content Development Activity

3.1 Summary

Content from the SNOMED CT® July 2021 International Edition release has been included, alongside additional components for use in Switzerland. 

This extension contains concepts, relationships and reference sets for healthcare professionals. 

3.2 New and Updated Content

New content in this release:

This is the 1st SNOMED CT Switzerland Edition Production release.

New and updated content

Concept statistics

The SNOMED Switzerland National Release Centre published ??????? new concepts, and these are available in the Switzerland Extension December release.

Table 1. New concepts in the Switzerland Edition December release

Total number of concepts

4

SNOMED  CT model component  (metadata)

1

Other Asian ethnic group (ethnic group)

1

Other black ethnic group (ethnic group)

1

Other ethnic, mixed origin (ethnic group)

1

Other concepts re-activated for use in Switzerland extension

On examination - height (finding)
On examination - irregular pulse (finding)
On examination - pulse rate (finding)
On examination - pulse rhythm regular (finding)
On examination-Left diabetic foot at risk (finding)
On examination-Right diabetic foot at risk (finding)
On examination - No left foot deformity (situation)
On examination - No left foot ulcer (situation)
On examination - No right foot deformity (situation)
On examination - No right foot ulcer (situation)

Relationships


Total active relationships199
Inactivation's 0
Total active descriptions271

 Refer to Appendix 1, Table 1.1 to view the new concepts.

 This content was derived through the dataset specification process and includes concepts from


Reference sets 




The SNOMED Switzerland National Release Centre promoted ??????? new concepts and these will be available in the SNOMED CT July 2021 International Edition release.

Refer to Appendix 2, Table 1.2 to view 


4 Technical notes

4.1 Known Issues

Known Issues are content or technical issues where the root cause is understood, and the resolution has been discussed and agreed but has yet to be implemented.  This can be due to a number of reasons, from lack of capacity within the current editing cycle, to the risk of impact to the stability of SNOMED CT if the fix were to be deployed at that stage in the Product lifecycle.  

For the SNOMED CT Managed Service - Switzerland Extension Release, the following Known Issues were identified, and agreed to be resolved in the next editing cycle:

Key Summary Description P
Loading...
Refresh

4.2 Resolved Issues

Resolved Issues are those where the resolution has been discussed and agreed, and has been implemented in time for this release. 

For the SNOMED CT Managed Service - Switzerland Extension Release, the following Issues were Resolved: 

Key Summary Description P
Loading...
Refresh


4.3 New Relationship Concrete Values files

Please be aware that the following new files have been added to the Switzerland Extension Release package, representing the new 

Concrete Domains content being introduced in this editing cycle, in line with the related changes to the International Edition Release:

    • xsct2_RelationshipConcreteValues_Delta_IE1000220_20211021.txt
    • xsct2_RelationshipConcreteValues_Snapshot_IE1000220_20211021.txt
    • xsct2_RelationshipConcreteValues_Full_IE1000220_20211021.txt



 

Appendix 1


Table 1.1


IdFSNSemTag
1601000220105Switzerland drugs module (core metadata concept)(core metadata concept)
1601000220105Switzerland drugs module (core metadata concept)(core metadata concept)
315281001Other Asian ethnic group (ethnic group)(ethnic group)
315279003Other black ethnic group (ethnic group)(ethnic group)
186019001Other ethnic, mixed origin (ethnic group)(ethnic group)

Appendix 2

Table 1.2

These drugs g=have been promoted to the International edition of SNOMED through the Content request service and will appear in the January 2022 International edition




aminophylline hydrate 225 mg prolonged-release tablet (clinical drug)17/06/2021Product
Product containing precisely biperiden hydrochloride 4 mg/1 each prolonged-release oral tablet (clinical drug)17/06/2021Product
Product containing precisely budesonide 9 mg/1 each prolonged-release oral tablet (clinical drug)17/06/2021Product
Product containing precisely clarithromycin (as clarithromycin citrate) 500 mg/1 each prolonged-release oral tablet (clinical drug)17/06/2021Product
Product containing precisely conjugated estrogens 0.625 mg/1 each prolonged-release oral tablet (clinical drug)17/06/2021Product
Product containing precisely conjugated estrogens 1.25mg/1 each prolonged-release oral tablet (clinical drug)17/06/2021Product
Product containing precisely galantamine (as galantamine hydrobromide) 16 mg/1 each prolonged-release hard capsule17/06/2021Product
Product containing precisely galantamine (as galantamine hydrobromide) 8mg/1 each dose prolonged release hard capsule (clinical drug)17/06/2021Product
Product containing precisely galantamine (as galantamine hydrobromide) 24 mg/1 each prolonged-release hard capsule(clinical drug)







Product containing precisely mesalazine 1 g/1 each prolonged-release oral tablet (clinical drug)17/06/2021Product
Product containing precisely mesalazine 2 g/1 sachet prolonged-release oral granules (clinical drug)17/06/2021Product
Product containing precisely mesalazine 4 g/1 sachet prolonged-release oral granules (clinical drug)17/06/2021Product
Product containing precisely nevirapine 100 mg/1 each prolonged-release oral tablet (clinical drug)17/06/2021Product
Product containing precisely paliperidone (as paliperidone palmitate) 200mg/1ml prolonged release suspension for injection (clinical drug)17/06/2021Product
Product containing precisely pramipexole (as pramipexole dihydrochloride monohydrate) 0.26 mg/1 each prolonged release oral tablet (clinical drug)17/06/2021Product
Product containing precisely pramipexole (as pramipexole dihydrochloride monohydrate) 0.52 mg/1 each prolonged release oral tablet (clinical drug)17/06/2021Product
Product containing precisely pramipexole (as pramipexole dihydrochloride monohydrate) 2.1 mg/1 each prolonged release oral tablet (clinical drug)17/06/2021Product
Product containing precisely pramipexole (as pramipexole dihydrochloride monohydrate) 3.15 mg/1 each prolonged release oral tablet (clinical drug)17/06/2021Product



Product containing precisely pramipexole (as pramipexole dihydrochloride monohydrate) 1.05 mg/1 each prolonged release oral tablet (clinical drug)17/06/2021Product
Product containing precisely quetiapine (as quetiapine fumarate) 150 mg/1 each prolonged-release oral tablet (clinical drug)17/06/2021Product
Product containing precisely quetiapine (as quetiapine fumarate) 50 mg/1 each prolonged-release oral tablet (clinical drug)17/06/2021Product
Product containing precisely ranolazine 375 mg/1 each prolonged-release oral tablet (clinical drug)17/06/2021Product
Product containing precisely ranolazine 500 mg/1 each prolonged-release oral tablet (clinical drug)17/06/2021Product
Product containing precisely ranolazine 750 mg/1 each prolonged-release oral tablet (clinical drug)17/06/2021Product
Product containing precisely tacrolimus (as tacrolimus monohydrate) 0.5 mg/1 each prolonged-release oral capsule (clinical drug)17/06/2021Product
Product containing precisely tacrolimus (as tacrolimus monohydrate) 0.75 mg/1 each prolonged-release oral tablet (clinical drug)17/06/2021Product
Product containing precisely tacrolimus (as tacrolimus monohydrate) 1 mg/1 each prolonged-release oral capsule (clinical drug)17/06/2021Product
Product containing precisely tacrolimus (as tacrolimus monohydrate) 1 mg/1 each prolonged-release oral tablet (clinical drug)17/06/2021Product
Product containing precisely tacrolimus (as tacrolimus monohydrate) 3 mg/1 each prolonged-release oral capsule (clinical drug)17/06/2021Product
Product containing precisely tacrolimus (as tacrolimus monohydrate) 4 mg/1 each prolonged-release oral tablet (clinical drug)17/06/2021Product
Product containing precisely tacrolimus (as tacrolimus monohydrate) 5 mg/1 each prolonged-release oral capsule (clinical drug)17/06/2021Product
Product containing precisely tamsulosin hydrochloride 400 mcg/1 each prolonged-release oral tablet (clinical drug)17/06/2021Product
Product containing precisely tapentadol (as tapentadol hydrochloride) 100 mg/1 each prolonged-release oral tablet (clinical drug)17/06/2021Product
Product containing precisely tapentadol (as tapentadol hydrochloride) 150 mg/1 each prolonged-release oral tablet (clinical drug)17/06/2021Product
Product containing precisely tapentadol (as tapentadol hydrochloride) 200 mg/1 each prolonged-release oral tablet (clinical drug)17/06/2021Product
Product containing precisely tapentadol (as tapentadol hydrochloride) 250 mg/1 each prolonged-release oral tablet (clinical drug)17/06/2021Product
Product containing precisely tapentadol (as tapentadol hydrochloride) 50 mg/1 each prolonged-release oral tablet (clinical drug)17/06/2021Product
Product containing precisely tofacitinib (as tofacitinib citrate) 11 mg/1 each prolonged-release oral tablet (clinical drug)17/06/2021Product






oduct containing precisely tolterodine tartrate 2 mg/1 each prolonged-release oral capsule (clinical drug)17/06/2021Product
Product containing precisely tolterodine tartrate 4 mg/1 each prolonged-release oral capsule (clinical drug)17/06/2021Product
Product containing precisely tramadol hydrochloride 50 mg/1 each prolonged-release oral tablet (clinical drug)17/06/2021Product
Product containing precisely venlafaxine (as venlafaxine hydrochloride) 37.5 mg/1 each prolonged-release oral capsule (clinical drug)17/06/2021Product
Product containing precisely venlafaxine (as venlafaxine hydrochloride) 37.5 mg/1 each prolonged-release oral tablet (clinical drug)17/06/2021Product
Product containing precisely alendronic acid (as alendronate sodium trihydrate) 70mg/100ml conventional release oral solution (clinical drug)17/06/2021Product
Product containing precisely ambroxol hydrochloride 17.86 mg/1 ml oral mucosal spray solution (clinical drug)17/06/2021Product
Product containing precisely atomoxetine (as atomoxetine hydrochloride) 4 mg/1 ml conventional release oral solution (clinical drug)17/06/2021Product
Product containing precisely brivaracetam 10 mg/1 ml conventional release oral solution (clinical drug)17/06/2021Product



duct containing precisely bromhexine hydrochloride 800 mcg/1 ml conventional release oral solution (clinical drug)17/06/2021Product
Product containing precisely clobazam 2 mg/1 ml conventional release oral suspension (clinical drug)17/06/2021Product
Product containing precisely clobazam 1 mg/1 ml conventional release oral suspension (clinical drug)17/06/2021Product
Product containing precisely clozapine 50 mg/1 ml oral suspension (clinical drug)17/06/2021Product
Product containing precisely colecalciferol 10000 IU/1 ml conventional release oral drops, solution (clinical drug)17/06/2021Product
Product containing precisely darunavir (as darunavir ethanolate) 100 mg/1 ml oral suspension17/06/2021Product
Product containing precisely deferiprone 100 mg/1 ml conventional release oral solution (clinical drug)17/06/2021Product
Product containing precisely desmopressin (as desmopressin acetate) 120 mcg/1 each conventional release oral lyophilisate (clinical drug)17/06/2021Produc

Concept

Modified

Topic

Product containing precisely desmopressin (as desmopressin acetate) 240 mcg/1 each conventional release oral lyophilisate (clinical drug)17/06/2021Product
Product containing precisely desmopressin (as desmopressin acetate) 25 mcg/1 each conventional release oral lyophilisate (clinical drug)17/06/2021Product
Product containing precisely desmopressin (as desmopressin acetate) 50 mcg/1 each conventional release oral lyophilisate (clinical drug)17/06/2021Product
Product containing precisely desmopressin (as desmopressin acetate) 60 mcg/1 each conventional release oral lyophilisate (clinical drug)17/06/2021Product




Approvals


Final Version

Date

Approver

Comments

0.1


Terance Shird

Approved

1.0

 

Theresa BarryApproved



Download .pdf here:







Draft Amendment History


Version

Date

Editor

Comments

0.1

 

Andrew AtkinsonInitial draft created
0.9

12/10/2020

Theresa BarryFinal draft
1.0

21/10/2020

Theresa BarryFinal fixes to stats etc


  • No labels